Display options
Cite
Pinto AE, Areia F, Pereira T, et al. Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer. Springerplus. 2013;2:375doi: 10.1186/2193-1801-2-375.
Pinto, A. E., Areia, F., Pereira, T., Cardoso, P., Aparício, M., Silva, G. L., Ferreira, M. C., & André, S. (2013). Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer. SpringerPlus, 2375. https://doi.org/10.1186/2193-1801-2-375
Pinto, António E, et al. "Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer." SpringerPlus vol. 2 (2013): 375. doi: https://doi.org/10.1186/2193-1801-2-375
Pinto AE, Areia F, Pereira T, Cardoso P, Aparício M, Silva GL, Ferreira MC, André S. Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer. Springerplus. 2013 Aug 09;2:375. doi: 10.1186/2193-1801-2-375. eCollection 2013. PMID: 24010033; PMCID: PMC3755814.
Copy Download .nbib Format: NLM
Share it on

Springerplus. 2013 Aug 09;2:375. doi: 10.1186/2193-1801-2-375. eCollection 2013.

Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer.

SpringerPlus

António E Pinto, Filipa Areia, Teresa Pereira, Paula Cardoso, Mariana Aparício, Giovani L Silva, Mónica C Ferreira, Saudade André

Affiliations

  1. Departamento de Matemática do Instituto Superior Técnico da Universidade Técnica de Lisboa, Lisboa, Portugal.

PMID: 24010033 PMCID: PMC3755814 DOI: 10.1186/2193-1801-2-375

Abstract

BACKGROUND: Accurate assessment of estrogen (ER) and progesterone (PR) receptors is critical in predicting the response to endocrine therapies in breast cancer.

MATERIAL AND METHODS: From a series of 360 patients with breast invasive carcinoma assessed for hormone receptors by immunohistochemistry (IHC) in the 90's, we re-analysed, on the same tumour material, the cases considered negative (n = 164), i.e., ER-/PR- (n = 95), ER+/PR- (n = 63) and ER-/PR+ (n=6), and 16 of 196 ER+/PR+ tumours with unfavourable outcome. Concordance between the previous IHC (Streptavidin-Biotin-Peroxidase) method and the current one (Peroxidase-Indirect-Polymer) was determined by the McNemar's test. Relapse-free (RFS) and overall survival (OS) were estimated by the Kaplan-Meier method.

RESULTS: From 101 ER- and 158 PR- cases, 38 (37.6%) and 58 (36.7%) became positive, increasing ER and PR expression from 71.9% and 56.1% to 82.5% and 72.2%, respectively (P<0.001). All 16 ER+/PR+ cases maintained their co-positivity, while all ER-/PR+ tumours changed to ER positive. Kaplan-Meier survival curves showed significant differences related to RFS and OS for PR, either in the whole series or in the subset (n = 151) submitted to hormonal treatment. The patients' subgroup with ER+/PR- tumours exhibited the worst prognosis.

CONCLUSION: The current IHC method improves the clinical usefulness of ER/PR assessment by decreasing the rate of false negative results.

Keywords: Breast cancer; Estrogen receptors; Immunohistochemistry; Progesterone receptors; Prognosis

References

  1. J Clin Oncol. 1999 May;17(5):1474-81 - PubMed
  2. Am J Clin Pathol. 2005 Jan;123(1):21-7 - PubMed
  3. J Clin Oncol. 2007 Oct 20;25(30):4772-8 - PubMed
  4. Ann Oncol. 2013 Jan;24(1):47-53 - PubMed
  5. Anticancer Res. 2005 May-Jun;25(3c):2535-42 - PubMed
  6. J Natl Compr Canc Netw. 2009 Sep;7 Suppl 6:S1-S21; quiz S22-3 - PubMed
  7. Histopathology. 1991 Nov;19(5):403-10 - PubMed
  8. Am J Clin Pathol. 2005 Jan;123(1):16-20 - PubMed
  9. Adv Anat Pathol. 2005 Jan;12(1):10-9 - PubMed
  10. J Clin Oncol. 2011 Sep 20;29(27):3715-6 - PubMed
  11. Ann Surg Oncol. 2013 May;20(5):1530-7 - PubMed
  12. Oncologist. 2008 Nov;13(11):1134-6 - PubMed
  13. Breast Cancer Res Treat. 2010 Apr;120(2):293-308 - PubMed
  14. J Clin Oncol. 2005 Oct 20;23(30):7721-35 - PubMed
  15. Nature. 2000 Aug 17;406(6797):747-52 - PubMed
  16. Arch Pathol Lab Med. 2010 Jul;134(7):e48-72 - PubMed
  17. Am J Clin Pathol. 1981 Jun;75(6):816-21 - PubMed
  18. J Clin Oncol. 2003 May 15;21(10):1973-9 - PubMed
  19. Am J Clin Pathol. 2001 Jan;115(1):44-58 - PubMed
  20. J Clin Oncol. 2011 Aug 1;29(22):2978-84 - PubMed
  21. Cancer. 2005 Jan 1;103(1):164-73 - PubMed
  22. Int J Biol Markers. 2003 Jan-Mar;18(1):7-12 - PubMed
  23. Breast Cancer Res Treat. 2011 Apr;126(2):421-30 - PubMed
  24. J Natl Cancer Inst. 2006 Nov 1;98(21):1571-81 - PubMed
  25. Virchows Arch. 2002 Oct;441(4):328-34 - PubMed
  26. Breast Cancer. 2004;11(3):267-75 - PubMed
  27. Cancer. 2012 Mar 15;118(6):1498-506 - PubMed
  28. Oncologist. 2011;16(3):276-85 - PubMed
  29. J Clin Oncol. 2008 Mar 1;26(7):1059-65 - PubMed
  30. J Natl Cancer Inst. 2008 Jun 18;100(12):836-7, 844 - PubMed
  31. Ann Oncol. 2009 Aug;20(8):1319-29 - PubMed
  32. J Clin Oncol. 2007 Sep 1;25(25):3846-52 - PubMed
  33. J Clin Oncol. 2006 Dec 20;24(36):5637-44 - PubMed
  34. J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61 - PubMed
  35. Breast Cancer Res Treat. 2009 Mar;114(2):287-99 - PubMed
  36. Int J Cancer. 2000 Mar 20;89(2):111-7 - PubMed

Publication Types